



Asian leishmaniac initiatives

Issue #1- 2015: summarized by KP Chang (11-15) from PI-provided Information

“Host-pathogen interaction in leishmaniasis” (In progress)

Syamal Roy, SN Bhattacharyya, CSIR- Indian Inst of Chemical Biology, Kolkata

Pradeep Das, Rajendra Memorial Research Institute of Medical Sciences, Patna

Poonam Salotra, Molecular Parasitology, National Institute of Pathology (ICMR), New Delhi

INDO-TRIT (Networking project - Indo-Belgian Research/Technology Cooperation) (Under consideration)

“Prenylation pathway enzyme structure-function analysis: New drug-targets of VL”(In progress)

Neeloo Singh, CSIR Cent Drug Res Inst, Lucknow, India/Andrea Ilari, Inst Mol Biol/Pathobiol of CNR (Italian National Research Council), Sapienza University of Rome, Italy

CSIR India-CNR Italy Cooperation Res Programs (Under consideration) (2016-2018)

“Proteomics of Brazil and India *Leishmania*: Drug target prediction/validation” (In progress)

Neeloo Singh, CSIR Cent Drug Res Inst, Lucknow, India/Camila I. de Oliveira, FIOCRUZ Salvador, Brazil

Priority Res Area/Red Biotech of Infectious Neglected Diseases

India-Brazil Binational Science and Biotech Cooperation programs (Under consideration) (2016-2019)

“Molecular mechanisms of *Leishmania donovani* paromomycin resistance” (2015-2018)

Poonam Salotra, National Institute of Pathology, New Delhi, India

ICMR (Indian Council of Medical Research, India)

“Clinical immunol/Parasitol of PKDL response to miltefosine and amphotericin B” (2015-2018).

Poonam Salotra, National Institute of Pathology, New Delhi, India

ICMR (Indian Council of Medical Research, India)

“Xenodiagnosis of VL, PKDL, asymptomatic subjects using Phlebotomine Sand Flies” (Since 2015)

Shyam Sundar, Banaras Hindu Univ, India/David Sacks *et al.*, NIAID, NIH, USA

BMGF (Bill & Melinda Gates Foundation, USA)

“Biomarkers of attenuation in the live attenuated vaccine candidate of *Leishmania donovani*” (2015-)

A. Selvapandiyan, Team Lead, Infectious Diseases, Institute of Molecular Medicine, New Delhi 110020, ICMR (Indian Council of Medical Research, India)

INSA-India International Senior Scientist Fellowship (2014)

Neeloo Singh – 2014 Awardee to initiate collaborative research projects on “Leishmania epidemiology/drug-resistance” by visiting colleagues at Ege University (Izmir), Celal Bayar University (Manisa) and Yildiz University (Istanbul), Turkey

“Genome-wide characterization of tRNA synthetases & their Paralogs from *Leishmania*” (2013-2016)

R Madhubala, Jawaharlal Nehru University, New Delhi, India

DBT (Department of Biotechnology, India)

“Modulation of Global changes in host cell by Intracellular pathogen *L donovani*” (2013-2016)

R Madhubala, Jawaharlal Nehru University, New Delhi, India

DST (Department of Science and Technology, India)



Worldleish

An International Congress on Leishmania & Leishmaniasis

www.worldleish.org

Asian leishmaniac initiatives (Con't)

Issue #1- 2015: summarized by KP Chang (11-15) from PI-provided Information

“Characterization of Vitamin C biosynthesis pathway as a drug target in *L donovani*,” (2012-2015)

R Madhubala, Jawaharlal Nehru University, New Delhi, India,
CSIR (Council of Scientific and Industrial Research) 37(1511)/11/EMR-II

Japan-Bangladesh collaboration-SuruyaKanta Research Center (SKKRC)to eliminate VL (since 2012)

Yoshitsugu Matsumoto, Chizu Sanjoba, Eisei Noiri, University of Tokyo, Japan/Mymensingh Medical College and Hospital, International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B) and CDC, Ministry of Health and Family Welfare, Bangladesh
SATREPS [Japan Agency for Medical Research and Development (AMED) /Japan Science and Technology Agency (JICA)]

Infectious Diseases of Poverty (since 2012)

Xiao-nong Zhou, Editor-in-Chief, Director of National Institute of Parasitic Diseases, Shanghai
Scientific journal launched in 2012 (IPF: 4.1), which publishes articles on leishmaniasis.

“Combination immunotherapy/ drug treatment to control chronic infectious diseases” (Since 2012)

Shyam Sundar Banaras Hindu University, India/Christian Engwerda, Queensland Inst Med Research
AISRF (Australia-India Strategic Research Fund)Indo-Australian S&T Fund
DBT (Department of Biotechnology, India)

“Programme support on Molecular Parasitology,” (2011-2016)

R. Madhubala, Jawaharlal Nehru University, New Delhi, India
DBT (Department of Biotechnology)-Centre for Excellence BT/01/CEIB/11/V/08

“Clinical/experimental immunology of centrin-KO live attenuated *Leishmania*” (2011-2014)

Anuradha Dube, CSIR Central Drug Research Institute/**A. Selvapandiyar**, Institute of Molecular Medicine/**P Salotra**, National Institute of Pathology, India/Hira Nakhasi, CBER, FDA, USA (Advisor).
DBT (Department of Biotechnology, India)

“Development of anti-leishmanial flavonoid compounds” (since 2010)

Larry M Chow, Honk Kong PolytechUnivesity, **Zhao-RongLun**, Zhonshang (Sun-Yat-Sen) University, Guangzhou, China
Hong Kong Res Grant Council/China Natural Science Foundation - Research Collaboration

“Visceral Leishmaniasis in Bihar States, India” (Since 2005)

Shyam Sundar, Banaras Hindu University, India
TMRC (Tropical Medicine Research Center) P-50, NIAID, NIH, USA



Worldleish

An International Congress on Leishmania & Leishmaniasis

www.worldleish.org

Asian leishmaniac initiatives (Con't)

Issue #1- 2015: summarized by KP Chang (11-15) from PI-provided Information

“Leishmania VL and PKDL strains ? whole genome sequence of PKDL strains” (Since 1998)

Sarman Singh, All India Institute of Medical Sciences, New Delhi, India

DBT (Department of Biotechnology, India)

“Diagnosis of visceral leishmaniasis in India” (since 1991)

Sarman Singh, All India Institute of Medical Sciences, New Delhi, India

DBT (Department of Biotechnology, India)